CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology, Inc. Common stock

CG Oncology is a privately held oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.

Our lead candidate, CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO® (nivolumab).

Whitesun Healthcare Ventures

WI Harper Group

Song Hong Fang

Ally Bridge Group

ORI Capital

Perseverance Capital Management

Camford Capital

Kissei Pharmaceutical

Decheng Capital

RA Capital Management

Sirona Capital

Acorn Bioventures

Longitude Capital

Malin Corporation

Foresite Capital

BVF Partners

TCG Crossover

Avidity Partners

Janus Henderson Investors

CG Oncology

Join Dr. Vijay Kasturi, CG Oncology’s Chief Medical Officer, at the 2024 American Urological Association (AUA) Annual Meeting in #SanAntonioTX. Dr. Kasturi will share how CG Oncology is advancing the fight against bladder cancer with innovative solutions at our booth #100 from May 3-5 at 12:30 pm CDT. He will provide insights into our pipeline, clinical trials, and the potential of cretostimogene grenadenorepvec as a therapeutic option.

📅 May 3-5, Booth #100
⏰ 12:30 pm (10 to 15 mins) 

Our team is looking forward to sharing our latest advancements for #NMIBC patients.

👉 More on the event here: auanet.org/AUA2024

#CGOncology #BladderCancer #UroOncology #CancerResearch #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #TherapeuticAdvances #AUA24

Each year, more than 80,000 people in the United States receive a #bladdercancer diagnosis. 🩺

CG Oncology is committed to addressing the unmet needs of these patients and focused on developing bladder-saving therapeutics. Join us in the Bladder Cancer Advocacy Network (BCAN) 2024 Walks to End Bladder Cancer, happening all across the country. These walks are a celebration of hope as we unite to advance research and provide support for patients and their loved ones. 

👉 Find a walk near you at https://bit.ly/3x65qD3 

#CGOncology #EndBladderCancer #BladderCancerAwareness #BladderCancer #UroOncology #CancerResearch #MedicalResearch #CancerSupport #BCANWalk2024 

CG Oncology is excited to share our updated results on cretostimogene grenadenorepvec at the 2024 American Urological Association (AUA) Annual Meeting in San Antonio, TX from May 3-6, 2024.  

Dr. Robert Svatek of UT Health San Antonio and Dr. Mark Tyson, M.D., M.P.H of Mayo Clinic Scottsdale, AZ, will present abstracts highlighting cretostimogene, while an oral presentation will feature the interim 12-month Phase 3 data from the BOND-003 trial. If you are attending #AUA2024, we invite you to join us and meet our team at booth #100. Cretostimogene has the potential to be a backbone therapy for patients diagnosed with bladder cancer. 

📖 For more information, read the full release: https://bit.ly/3PEUbI0 

#CGOncology #BladderCancer #CancerResearch #UroOncology #MedicalResearch #CancerResearch #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #OncologyBreakthrough #TherapeuticAdvances #AUA24

🧬 Excitement is building for #AUA2024! Join us at the 2024 American Urological Association (AUA) Annual Meeting, taking place in #SanAntonioTX from May 3-6.

Meet CG Oncology’s Medical Team at Booth #100 and explore the MoA of cretostimogene grenadenorepvec through Virtual Reality. This is an incredible opportunity to gain insights into the future of #bladdercancer therapy and learn how our pipeline and clinical trial programs can complement your practice. More details coming soon!

🗓️ Learn more here: auanet.org/AUA2024

#CGOncology #BladderCancer #CancerResearch #UroOncology #MedicalResearch #CancerResearch #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #OncologyBreakthrough #TherapeuticAdvances #AUA24

CG Oncology is growing! We recently welcomed some exceptionally talented team members who will be joining with us in Attacking Bladder Cancer for a Better Tomorrow™. Welcome to CG Oncology Adrian Knoth, M.Sc, PMP, Anthony Fernandez, PharmD, MSL-BC, Davis Bauman, Shelja Patel, PharmD, RPh, BCMAS and Victoria D'Anthony. If you are interested in joining our team of intelligent and passionate team members that share our Vision, Mission and Values, please visit our Careers Page: https://lnkd.in/e-UiUYdg

Today marks another step forward in our ongoing effort to transform the treatment landscape for #bladdercancer. The first patient has been dosed in the PIVOT-006 Phase 3 trial, which is investigating cretostimogene grenadenorepvec as an investigational drug for the treatment of Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (#NMIBC) following transurethral resection of the bladder tumor (#TURBT).  

With over 80,000 individuals diagnosed annually with bladder cancer in the United States, the PIVOT-006 study addresses the unmet medical need for patients facing limited treatment options. Dr. Neal Shore, MD, FACS of Carolina Urologic Research Center confirmed the potential impact of this therapy: “Cretostimogene is a novel therapy which has the potential to be a paradigm shift in how we might manage the ongoing burden of this highly recurrent aspect of bladder cancer.”
 
Learn more about the PIVOT-006 study and how CG Oncology is committed to developing novel bladder-sparing therapeutics that improve patient outcomes.

📄 Read the full release: https://bit.ly/49AOqTO 
 
#Urology #ClinicalTrials #UrothelialCancer #CancerResearch #MedicalResearch #PatientCare #Immunotherapy #Therapeutics #CGOncology #PIVOT006

	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24
net income	-8.39M -	-8.67M 3.28%	-11.62M 34.04%	-12.21M 5.08%	-16.12M 32.02%	-16.93M 5.06%	-18.90M 11.63%
depreciation and amortization	4K -	4K 0%	4K 0%	5K 25%	4K 20%	4K 0%	7K 75%
deferred income tax
stock based compensation	148K -	179K 20.95%	177K 1.12%	394K 122.60%	778K 97.46%	1.52M 94.99%
change in working capital	1.30M -	373K 71.40%	286K 23.32%	618K 116.08%	2.16M 249.84%	-8.40M 488.48%	3.01M 135.80%
accounts receivables
inventory
accounts payables	186K -	-9K 104.84%	49K 644.44%	590K 1,104.08%	1.38M 134.24%	1.42M 2.53%	-168K 111.86%
other working capital	1.12M -	382K 65.83%			780K -	-9.82M 1,358.46%	3.27M 133.26%
other non cash items	107K -	125K 16.82%	621K 396.80%	87K 85.99%	-14K 116.09%	-2.09M 14,857.14%	-50K 97.61%
net cash provided by operating activities	-6.83M -	-7.99M 16.94%	-10.79M 35.06%	-10.85M 0.56%	-16.06M 48.08%	-26.01M 61.96%	-16.12M 38.03%
investments in property plant and equipment	1K -		-6K -	6K 200%		-12K -	-14K 16.67%
acquisitions net
purchases of investments	-55.34M -	-78.70M 42.22%	-32.35M 58.90%	-27.09M 16.25%	-379.47M 1,300.73%	-453.30M 19.45%	-206.34M 54.48%
sales maturities of investments			135.71M -			145.87M -	170.13M 16.63%
other investing activites	-55.34M -	-78.70M 42.22%			16.94M -	-307.43M 1,914.51%
net cash used for investing activites	-55.34M -	-78.70M 42.22%	103.36M 231.33%	-162.80M 257.51%	16.94M 110.41%	-307.44M 1,914.58%	-36.23M 88.22%
debt repayment		-833K -	-15.39M 1,747.54%	-67K 99.56%	-1K 98.51%	-365K 36,400%
common stock issued	148K -					403.02M -	40K 99.99%
common stock repurchased
dividends paid
other financing activites	56.70M -	68K 99.88%			-3.15M -	-3.39M 7.49%
net cash used provided by financing activities	56.70M -	-765K 101.35%	-15.22M 1,890.20%	105.88M 795.41%	-2.89M 102.73%	402.66M 14,037.63%	40K 99.99%
effect of forex changes on cash
net change in cash	-5.47M -	-87.45M 1,499.31%	77.35M 188.45%	-67.77M 187.61%	-2.01M 97.04%	69.20M 3,548.03%	-52.31M 175.59%
cash at beginning of period	93.61M -	88.14M 5.84%	693K 99.21%	78.04M 11,161.04%	10.27M 86.84%	8.27M 19.54%	77.47M 837.19%
cash at end of period	88.14M -	693K 99.21%	78.04M 11,161.04%	10.27M 86.84%	8.27M 19.54%	77.47M 837.19%	25.16M 67.52%
operating cash flow	-6.83M -	-7.99M 16.94%	-10.79M 35.06%	-10.85M 0.56%	-16.06M 48.08%	-26.01M 61.96%	-16.12M 38.03%
capital expenditure	1K -		-6K -	6K 200%		-12K -	-14K 16.67%
free cash flow	-6.83M -	-7.99M 16.96%	-10.79M 35.14%	-10.84M 0.44%	-16.06M 48.16%	-26.02M 62.03%	-16.13M 38.00%

CGON

COM:CGONCOLOGY

CG Oncology

Last Close

36.68

30/08 20:00

Market Cap

2.19B

Beta: -

Volume Today

544.38K

Avg: -

Preview